Brief: Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody
17/07/2024 12:53
July 17 (Reuters) - Immutep Ltd IMM.AX :
* IMMUTEP LTD -RECEIVES REGULATORY CLEARANCE FOR PHASE I
STUDY OF
FIRST-IN-CLASS LAG-3 AGONIST ANTIBODY DESIGNED TO TREAT
AUTOIMMUNE DISEASES
* IMMUTEP LTD -STUDY EXPECTED TO ENROL FIRST PARTICIPANTS
DURING
Q3 CY2024
Source text for Eikon: ID:n0001193125-24-180005
Further company coverage: IMM.AX
((Reuters.Briefs@thomsonreuters.com;))